{"denoms":[{"counts":[{"groupId":"OG000","value":"0"}],"units":"Participants"}],"description":"The primary objective of this study is to assess the effectiveness of MV-NIS therapy for people with relapsed/refractory myeloma when given with cyclophosphamide","groups":[{"description":"MV-NIS: one dose in conjunction with a 4 day course intravenously","id":"OG000","title":"MV-NIS + Cyclophosphamide"}],"populationDescription":"Only two subjects were enrolled. Both passed away while enrolled. No data were collected.","reportingStatus":"POSTED","timeFrame":"1 year","title":"The Effectiveness of MV-NIS Therapy as Measured by the International Myeloma Working Group (IMWG) Guidelines","type":"PRIMARY"}